What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?

Simple item page
dc.contributor.authorWang, Wei‐Kang
dc.contributor.authorLu, Wen‐Min
dc.contributor.authorKweh, Qian Long
dc.contributor.authorTruong, Hoang Tu Nhi
dc.date.accessioned2020-02-25T14:18:16Z
dc.date.available2020-02-25T14:18:16Z
dc.date.copyright2020
dc.date.issued2020
dc.descriptionThis article is not available at CUD collection. The version of scholarly record of this Article is published in JManagerial and Decision Economics (2020), available online at: https://doi.org/10.1002/mde.3135.en_US
dc.description.abstractThis paper investigates how patents and research and development (R&D) spikes affect the corporate performance of 863 firm-year observations of U.S. biopharmaceutical companies. First, a dynamic data envelopment analysis model is adopted to evaluate the performance of the U.S. biopharmaceutical companies. Then, ordinary least squares regression is used to explore the effects of three patent-related variables (patent counts, citations, and claims) and R&D spikes on corporate performance. This study finds positive impacts of patent counts, citations, and claims on corporate performance. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance. © 2020 John Wiley & Sons, Ltd.en_US
dc.identifier.citationWang, W., Lu, W., Kweh, Q.L. & Truong, H.T.N. (2020). What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance? Managerial and Decision Economics. https://doi.org/10.1002/mde.3135en_US
dc.identifier.issn01436570
dc.identifier.urihttp://hdl.handle.net/20.500.12519/164
dc.identifier.urihttps://doi.org/10.1002/mde.3135
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Ltden_US
dc.relationAuthors Affiliations: Department of Accounting, Yuan Ze University, Taoyuan City, Taiwan; Department of International Business Administration, Chinese Culture University, Taipei, Taiwan; Faculty of Management, Canadian University Dubai, Dubai, United Arab Emirates
dc.rightsLicense to reuse the abstract has been secured from John Wiley and Sons and Copyright Clearance Center.
dc.rights.holderCopyright : 2020 John Wiley & Sons, Ltd.
dc.rights.licenseLicense Number: 5241360258934 License date: Feb 03, 2022
dc.rights.urihttps://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=e4b412f6-6c72-409d-89b6-c7864bbab19d
dc.subjectIntellectual Property-Rightsen_US
dc.subjectMarket Valueen_US
dc.subjectOperating Performanceen_US
dc.subjectContextual Variables
dc.subjectFirm Value
dc.subjectInnovation
dc.subjectEfficiency
dc.subjectProductivity
dc.subjectInvestment
dc.subjectImpact
dc.titleWhat do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?en_US
dc.typeArticleen_US

Files

Collections

Accounting & Finance